Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Computer-aided pulmonary image analysis in small animal models.

Xu Z, Bagci U, Mansoor A, Kramer-Marek G, Luna B, Kubler A, Dey B, Foster B, Papadakis GZ, Camp JV, Jonsson CB, Bishai WR, Jain S, Udupa JK, Mollura DJ.

Med Phys. 2015 Jul;42(7):3896. doi: 10.1118/1.4921618.

PMID:
26133591
2.

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, Capala J, Ioannis R, Harris AL, Kong A.

Oncotarget. 2014 Aug 15;5(15):5934-49.

3.

Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies.

Adesina SK, Holly A, Kramer-Marek G, Capala J, Akala EO.

J Pharm Sci. 2014 Aug;103(8):2546-55. doi: 10.1002/jps.24061. Epub 2014 Jun 24.

PMID:
24961596
4.

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A.

Oncotarget. 2014 Aug 30;5(16):6633-46.

5.

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

Nafi S, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, Capala J, Ioannis R, Harris AL, Kong A.

Oncotarget. 2014 Apr 17. [Epub ahead of print]

6.

Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.

Kramer-Marek G, Gore J, Korc M.

Cancer Lett. 2013 Dec 1;341(2):132-8. doi: 10.1016/j.canlet.2013.08.008. Epub 2013 Aug 11. Review.

7.

Automated computer quantification of breast cancer in small-animal models using PET-guided MR image co-segmentation.

Bagci U, Kramer-Marek G, Mollura DJ.

EJNMMI Res. 2013 Jul 5;3(1):49. doi: 10.1186/2191-219X-3-49.

8.

Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.

Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.

J Nucl Med. 2012 Oct;53(10):1592-600. doi: 10.2967/jnumed.111.102293. Epub 2012 Aug 23.

9.

Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy.

Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H.

BMC Cancer. 2012 Aug 8;12:345. doi: 10.1186/1471-2407-12-345.

10.

Recent advances in optical cancer imaging of EGF receptors.

Kramer-Marek G, Longmire MR, Choyke PL, Kobayashi H.

Curr Med Chem. 2012;19(28):4759-66. Review.

PMID:
22873662
11.

PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.

Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Aras O, Zielinski R, Seidel J, Choyke P, Capala J.

J Nucl Med. 2012 Jun;53(6):939-46. doi: 10.2967/jnumed.111.100354. Epub 2012 May 11. Erratum in: J Nucl Med. 2012 Jul;53(7):1169. Omer, Aras [corrected to Aras, Omer].

12.

Can PET imaging facilitate optimization of cancer therapies?

Kramer-Marek G, Capala J.

Curr Pharm Des. 2012;18(18):2657-69. Review.

PMID:
22512443
13.

The role of nuclear medicine in modern therapy of cancer.

Kramer-Marek G, Capala J.

Tumour Biol. 2012 Jun;33(3):629-40. doi: 10.1007/s13277-012-0373-8. Epub 2012 Mar 24. Review.

PMID:
22446937
14.

Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model.

Kramer-Marek G, Gijsen M, Kiesewetter DO, Bennett R, Roxanis I, Zielinski R, Kong A, Capala J.

J Nucl Med. 2012 Apr;53(4):629-37. doi: 10.2967/jnumed.111.096685. Epub 2012 Mar 12.

15.

Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells.

Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J, Bouchelouche K.

Mol Biol Rep. 2011 Oct;38(7):4237-43. doi: 10.1007/s11033-010-0442-2. Epub 2011 Jul 14.

16.

68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET.

Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J.

Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):1967-76. doi: 10.1007/s00259-011-1810-4. Epub 2011 Apr 20.

17.

HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging.

Lyakhov I, Zielinski R, Kuban M, Kramer-Marek G, Fisher R, Chertov O, Bindu L, Capala J.

Chembiochem. 2010 Feb 15;11(3):345-50. doi: 10.1002/cbic.200900532.

18.

Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.

Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R, Capala J.

J Immunother. 2009 Oct;32(8):817-25. doi: 10.1097/CJI.0b013e3181ad4d5d.

19.

Radiolabeling of HER2 specific Affibody(R) molecule with F-18.

Kiesewetter DO, Krämer-Marek G, Ma Y, Capala J.

J Fluor Chem. 2008 Sep;129(9):799-805.

20.

Comparison of photodynamic efficacy of tetraarylporphyrin pegylated or encapsulated in liposomes: in vitro studies.

Nawalany K, Rusin A, Kepczyński M, Mikhailov A, Kramer-Marek G, Snietura M, Połtowicz J, Krawczyk Z, Nowakowska M.

J Photochem Photobiol B. 2009 Oct 6;97(1):8-17. doi: 10.1016/j.jphotobiol.2009.07.005. Epub 2009 Jul 12.

PMID:
19665390
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk